Señales en vivo de OVID | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 16:00):

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States...

Stats
Volumen de hoy	77 179.00
Volumen promedio	214 486
Capitalización de mercado	216.68M
EPS	$0 ( 2024-05-03 )
Próxima fecha de ganancias	( $-0.210 ) 2024-06-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.14
ATR14	$0.00800 (0.26%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-18	Levin Jeremy M	Buy	18 248	Common Stock
2024-02-22	Tardio Jason	Buy	168 750	Stock Option (Right to Buy)
2024-02-22	Tardio Jason	Buy	28 125	Common Stock
2024-02-22	Rona Jeffrey A	Buy	28 125	Common Stock
2024-02-22	Rona Jeffrey A	Buy	168 750	Stock Option (Right to Buy)

INSIDER POWER
23.21
Last 96 transactions
Buy: 16 581 029 \| Sell: 7 414 277

Volumen Correlación

Largo: -0.02 (neutral)

Corto: 0.35 (neutral)

Signal:(64.955) Neutral

Ovid Therapeutics Inc Correlación

10 Correlaciones Más Positivas
RMRM	0.864

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Ovid Therapeutics Inc Correlación - Moneda/Commodity

-0.23
( neutral )

-0.45
( neutral )

0.00
( neutral )

0.32
( neutral )

-0.57
( weak negative )

Ovid Therapeutics Inc Finanzas

Annual	2023
Ingresos:	$391 695
Beneficio Bruto:	$-1.20M (-307.61 %)
EPS:	$-0.740

FY	2023
Ingresos:	$391 695
Beneficio Bruto:	$-1.20M (-307.61 %)
EPS:	$-0.740

FY	2022
Ingresos:	$1.50M
Beneficio Bruto:	$121 142 (8.06 %)
EPS:	$-0.730

FY	2021
Ingresos:	$208 383
Beneficio Bruto:	$208 383 (100.00 %)
EPS:	$0.00182

Financial Reports:

No articles found.

Ovid Therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.